XML 35 R78.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and Other Intangibles - Other Intangibles Footnotes (Detail) (USD $)
12 Months Ended
Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]  
Divestitures $ 68,540,000us-gaap_ImpairmentOfIntangibleAssetsFinitelived [1]
Intangible assets, accumulated amortization, reduction 27,584,000alb_RemovalofAccumulatedAmortizationofIntangibleAssetsFromImpairment [1]
Trade Names  
Finite-Lived Intangible Assets [Line Items]  
Indefinite-lived intangible asset, gross carrying amount 9,200,000alb_IndefiniteLivedIntangibleAssetsGrossCarryingAmount
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_TradeNamesMember
Antioxidant, Ibuprofen and Propofol Assets - Discontinued Operations  
Finite-Lived Intangible Assets [Line Items]  
Divestitures 68,540,000us-gaap_ImpairmentOfIntangibleAssetsFinitelived
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
Intangible assets, accumulated amortization, reduction $ 27,584,000alb_RemovalofAccumulatedAmortizationofIntangibleAssetsFromImpairment
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
[1] In 2014 we reduced intangible assets by $68.5 million and related accumulated amortization by $27.6 million in connection with the sale of our antioxidant, ibuprofen and propofol businesses and assets which closed on September 1, 2014. See Note 2 “Discontinued Operations” for additional information about this transaction.